#FORMAT=WebAnno TSV 3.2
#T_SP=webanno.custom.Referent|entity|infstat
#T_RL=webanno.custom.Coref|type|BT_webanno.custom.Referent


#Text=1. Introduction
1-1	0-2	1.	_	_	_	_
1-2	3-15	Introduction	abstract	new	_	_

#Text=Debilitating , unexplained provoked localized vulvar pain or vulvodynia affects a significant proportion ( ~8 % ) of women and is epidemiologically linked to a history of both seasonal and contact allergies .
2-1	16-28	Debilitating	_	_	_	_
2-2	29-30	,	_	_	_	_
2-3	31-42	unexplained	abstract[2]|abstract[3]	new[2]|new[3]	coref|coref|coref|coref	4-22[23_2]|5-34[38_3]|4-22[23_2]|5-34[38_3]
2-4	43-51	provoked	abstract[2]|abstract[3]	new[2]|new[3]	_	_
2-5	52-61	localized	abstract[2]|abstract[3]	new[2]|new[3]	_	_
2-6	62-68	vulvar	abstract[2]|abstract[3]	new[2]|new[3]	_	_
2-7	69-73	pain	abstract[2]|abstract[3]	new[2]|new[3]	_	_
2-8	74-76	or	abstract[3]	new[3]	_	_
2-9	77-87	vulvodynia	abstract[3]|substance	new[3]|new	coref	11-22
2-10	88-95	affects	_	_	_	_
2-11	96-97	a	quantity[5]	new[5]	appos	2-15[6_5]
2-12	98-109	significant	quantity[5]	new[5]	_	_
2-13	110-120	proportion	quantity[5]	new[5]	_	_
2-14	121-122	(	_	_	_	_
2-15	123-125	~8	quantity[6]	giv[6]	_	_
2-16	126-127	%	quantity[6]	giv[6]	_	_
2-17	128-129	)	_	_	_	_
2-18	130-132	of	_	_	_	_
2-19	133-138	women	person	new	_	_
2-20	139-142	and	_	_	_	_
2-21	143-145	is	_	_	_	_
2-22	146-163	epidemiologically	_	_	_	_
2-23	164-170	linked	_	_	_	_
2-24	171-173	to	_	_	_	_
2-25	174-175	a	abstract[8]	new[8]	_	_
2-26	176-183	history	abstract[8]	new[8]	_	_
2-27	184-186	of	abstract[8]	new[8]	_	_
2-28	187-191	both	abstract[8]|abstract[9]	new[8]|new[9]	_	_
2-29	192-200	seasonal	abstract[8]|abstract[9]	new[8]|new[9]	_	_
2-30	201-204	and	abstract[8]|abstract[9]	new[8]|new[9]	_	_
2-31	205-212	contact	abstract[8]|abstract[9]	new[8]|new[9]	_	_
2-32	213-222	allergies	abstract[8]|abstract[9]	new[8]|new[9]	_	_
2-33	223-224	.	_	_	_	_

#Text=Vulvar biopsies from diagnosed patients show increases in mast cells and nerves .
3-1	225-231	Vulvar	person|abstract[11]	new|new[11]	coref|coref	10-24|10-24
3-2	232-240	biopsies	abstract[11]	new[11]	_	_
3-3	241-245	from	abstract[11]	new[11]	_	_
3-4	246-255	diagnosed	abstract[11]|person[12]	new[11]|new[12]	_	_
3-5	256-264	patients	abstract[11]|person[12]	new[11]|new[12]	_	_
3-6	265-269	show	_	_	_	_
3-7	270-279	increases	event[13]	new[13]	_	_
3-8	280-282	in	event[13]	new[13]	_	_
3-9	283-287	mast	event[13]|object|object[15]	new[13]|new|new[15]	coref|coref|coref|coref	5-42[40_15]|6-5|5-42[40_15]|6-5
3-10	288-293	cells	event[13]|object[15]	new[13]|new[15]	_	_
3-11	294-297	and	event[13]	new[13]	_	_
3-12	298-304	nerves	event[13]|abstract	new[13]|new	_	_
3-13	305-306	.	_	_	_	_

#Text=To recapitulate and dissect the pathobiology of allergy-driven tactile sensitivity and to inform novel therapies , we established mouse models of allergy-driven genital pain .
4-1	307-309	To	_	_	_	_
4-2	310-322	recapitulate	_	_	_	_
4-3	323-326	and	_	_	_	_
4-4	327-334	dissect	_	_	_	_
4-5	335-338	the	abstract[17]	new[17]	_	_
4-6	339-351	pathobiology	abstract[17]	new[17]	_	_
4-7	352-354	of	abstract[17]	new[17]	_	_
4-8	355-369	allergy-driven	abstract[17]|abstract[18]	new[17]|new[18]	coref	15-43[137_18]
4-9	370-377	tactile	abstract[17]|abstract[18]	new[17]|new[18]	_	_
4-10	378-389	sensitivity	abstract[17]|abstract[18]	new[17]|new[18]	_	_
4-11	390-393	and	_	_	_	_
4-12	394-396	to	_	_	_	_
4-13	397-403	inform	_	_	_	_
4-14	404-409	novel	abstract[19]	new[19]	_	_
4-15	410-419	therapies	abstract[19]	new[19]	_	_
4-16	420-421	,	_	_	_	_
4-17	422-424	we	person	acc	ana	5-1
4-18	425-436	established	_	_	_	_
4-19	437-442	mouse	animal|abstract[22]	new|new[22]	coref|coref|coref|coref	12-4|12-1[110_22]|12-4|12-1[110_22]
4-20	443-449	models	abstract[22]	new[22]	_	_
4-21	450-452	of	abstract[22]	new[22]	_	_
4-22	453-467	allergy-driven	abstract[22]|abstract[23]	new[22]|giv[23]	coref	5-34[37_23]
4-23	468-475	genital	abstract[22]|abstract[23]	new[22]|giv[23]	_	_
4-24	476-480	pain	abstract[22]|abstract[23]	new[22]|giv[23]	_	_
4-25	481-482	.	_	_	_	_

#Text=We have shown that contact hypersensitivity to the commonly used laboratory haptens oxazolone ( Ox ) on the labiar skin or dinitrofluorobenzene ( DNFB ) on the labiar skin or vaginal canal induces persistent tactile genital pain and increased accumulation of mast cells in the labiar tissues of outbred , female ND4 mice well beyond the resolution of visible inflammation .
5-1	483-485	We	person	giv	ana	7-3
5-2	486-490	have	_	_	_	_
5-3	491-496	shown	_	_	_	_
5-4	497-501	that	_	_	_	_
5-5	502-509	contact	_	_	_	_
5-6	510-526	hypersensitivity	abstract[25]	new[25]	coref	7-21[0_25]
5-7	527-529	to	abstract[25]	new[25]	_	_
5-8	530-533	the	abstract[25]|substance[28]	new[25]|new[28]	_	_
5-9	534-542	commonly	abstract[25]|substance[28]	new[25]|new[28]	_	_
5-10	543-547	used	abstract[25]|substance[28]	new[25]|new[28]	_	_
5-11	548-558	laboratory	abstract[25]|place|substance[28]	new[25]|new|new[28]	_	_
5-12	559-566	haptens	abstract[25]|animal|substance[28]	new[25]|new|new[28]	_	_
5-13	567-576	oxazolone	abstract[25]|substance[28]	new[25]|new[28]	_	_
5-14	577-578	(	_	_	_	_
5-15	579-581	Ox	person	new	_	_
5-16	582-583	)	_	_	_	_
5-17	584-586	on	_	_	_	_
5-18	587-590	the	object[30]|abstract[31]	new[30]|new[31]	coref|coref|coref|coref	5-27[34_30]|5-27[35_31]|5-27[34_30]|5-27[35_31]
5-19	591-597	labiar	object[30]|abstract[31]	new[30]|new[31]	_	_
5-20	598-602	skin	object[30]|abstract[31]	new[30]|new[31]	_	_
5-21	603-605	or	abstract[31]	new[31]	_	_
5-22	606-626	dinitrofluorobenzene	abstract[31]|substance	new[31]|new	_	_
5-23	627-628	(	_	_	_	_
5-24	629-633	DNFB	object	new	_	_
5-25	634-635	)	_	_	_	_
5-26	636-638	on	_	_	_	_
5-27	639-642	the	object[34]|abstract[35]	giv[34]|giv[35]	coref|coref|coref|coref	9-31[86_34]|9-31[87_35]|9-31[86_34]|9-31[87_35]
5-28	643-649	labiar	object[34]|abstract[35]	giv[34]|giv[35]	_	_
5-29	650-654	skin	object[34]|abstract[35]	giv[34]|giv[35]	_	_
5-30	655-657	or	abstract[35]	giv[35]	_	_
5-31	658-665	vaginal	abstract[35]|place[36]	giv[35]|new[36]	coref	6-21[52_36]
5-32	666-671	canal	abstract[35]|place[36]	giv[35]|new[36]	_	_
5-33	672-679	induces	_	_	_	_
5-34	680-690	persistent	abstract[37]|abstract[38]	giv[37]|giv[38]	coref|coref	6-25[53_37]|6-25[53_37]
5-35	691-698	tactile	abstract[37]|abstract[38]	giv[37]|giv[38]	_	_
5-36	699-706	genital	abstract[37]|abstract[38]	giv[37]|giv[38]	_	_
5-37	707-711	pain	abstract[37]|abstract[38]	giv[37]|giv[38]	_	_
5-38	712-715	and	abstract[38]	giv[38]	_	_
5-39	716-725	increased	abstract[38]|abstract[39]	giv[38]|new[39]	_	_
5-40	726-738	accumulation	abstract[38]|abstract[39]	giv[38]|new[39]	_	_
5-41	739-741	of	abstract[38]|abstract[39]	giv[38]|new[39]	_	_
5-42	742-746	mast	abstract[38]|abstract[39]|object[40]	giv[38]|new[39]|giv[40]	coref	6-4[47_40]
5-43	747-752	cells	abstract[38]|abstract[39]|object[40]	giv[38]|new[39]|giv[40]	_	_
5-44	753-755	in	abstract[38]|abstract[39]|object[40]	giv[38]|new[39]|giv[40]	_	_
5-45	756-759	the	abstract[38]|abstract[39]|object[40]|place[41]	giv[38]|new[39]|giv[40]|new[41]	_	_
5-46	760-766	labiar	abstract[38]|abstract[39]|object[40]|place[41]	giv[38]|new[39]|giv[40]|new[41]	_	_
5-47	767-774	tissues	abstract[38]|abstract[39]|object[40]|place[41]	giv[38]|new[39]|giv[40]|new[41]	_	_
5-48	775-777	of	abstract[38]|abstract[39]|object[40]|place[41]	giv[38]|new[39]|giv[40]|new[41]	_	_
5-49	778-785	outbred	abstract[38]|abstract[39]|object[40]|place[41]	giv[38]|new[39]|giv[40]|new[41]	_	_
5-50	786-787	,	abstract[38]|abstract[39]|object[40]|place[41]	giv[38]|new[39]|giv[40]|new[41]	_	_
5-51	788-794	female	abstract[38]|abstract[39]|object[40]|place[41]|animal[42]	giv[38]|new[39]|giv[40]|new[41]|new[42]	coref	7-29[67_42]
5-52	795-798	ND4	abstract[38]|abstract[39]|object[40]|place[41]|animal[42]	giv[38]|new[39]|giv[40]|new[41]|new[42]	_	_
5-53	799-803	mice	abstract[38]|abstract[39]|object[40]|place[41]|animal[42]	giv[38]|new[39]|giv[40]|new[41]|new[42]	_	_
5-54	804-808	well	abstract[38]|abstract[39]|object[40]|place[41]|animal[42]	giv[38]|new[39]|giv[40]|new[41]|new[42]	_	_
5-55	809-815	beyond	abstract[38]|abstract[39]|object[40]|place[41]|animal[42]	giv[38]|new[39]|giv[40]|new[41]|new[42]	_	_
5-56	816-819	the	abstract[38]|abstract[39]|object[40]|place[41]|animal[42]|abstract[43]	giv[38]|new[39]|giv[40]|new[41]|new[42]|new[43]	_	_
5-57	820-830	resolution	abstract[38]|abstract[39]|object[40]|place[41]|animal[42]|abstract[43]	giv[38]|new[39]|giv[40]|new[41]|new[42]|new[43]	_	_
5-58	831-833	of	abstract[38]|abstract[39]|object[40]|place[41]|animal[42]|abstract[43]	giv[38]|new[39]|giv[40]|new[41]|new[42]|new[43]	_	_
5-59	834-841	visible	abstract[38]|abstract[39]|object[40]|place[41]|animal[42]|abstract[43]|abstract[44]	giv[38]|new[39]|giv[40]|new[41]|new[42]|new[43]|new[44]	coref	15-33[134_44]
5-60	842-854	inflammation	abstract[38]|abstract[39]|object[40]|place[41]|animal[42]|abstract[43]|abstract[44]	giv[38]|new[39]|giv[40]|new[41]|new[42]|new[43]|new[44]	_	_
5-61	855-856	.	_	_	_	_

#Text=Chemical depletion of labiar mast cells reduced Ox-driven painful responses and therapeutic topical administration of Δ-9-tetrahydrocannabinol ( THC ) in the vaginal canal alleviated DNFB-induced pain and reduced numbers of accumulated mast cells in the affected tissue .
6-1	857-865	Chemical	abstract[45]	new[45]	_	_
6-2	866-875	depletion	abstract[45]	new[45]	_	_
6-3	876-878	of	abstract[45]	new[45]	_	_
6-4	879-885	labiar	abstract[45]|object[47]	new[45]|giv[47]	coref	6-31[55_47]
6-5	886-890	mast	abstract[45]|object|object[47]	new[45]|giv|giv[47]	_	_
6-6	891-896	cells	abstract[45]|object[47]	new[45]|giv[47]	_	_
6-7	897-904	reduced	_	_	_	_
6-8	905-914	Ox-driven	abstract[48]	new[48]	coref	9-23[83_48]
6-9	915-922	painful	abstract[48]	new[48]	_	_
6-10	923-932	responses	abstract[48]	new[48]	_	_
6-11	933-936	and	_	_	_	_
6-12	937-948	therapeutic	organization[49]	new[49]	_	_
6-13	949-956	topical	organization[49]	new[49]	_	_
6-14	957-971	administration	organization[49]	new[49]	_	_
6-15	972-974	of	organization[49]	new[49]	_	_
6-16	975-999	Δ-9-tetrahydrocannabinol	organization[49]|abstract	new[49]|new	appos	6-18
6-17	1000-1001	(	_	_	_	_
6-18	1002-1005	THC	abstract	giv	coref	16-13
6-19	1006-1007	)	_	_	_	_
6-20	1008-1010	in	_	_	_	_
6-21	1011-1014	the	place[52]	giv[52]	coref	16-16[144_52]
6-22	1015-1022	vaginal	place[52]	giv[52]	_	_
6-23	1023-1028	canal	place[52]	giv[52]	_	_
6-24	1029-1039	alleviated	_	_	_	_
6-25	1040-1052	DNFB-induced	abstract[53]	giv[53]	coref	7-24[65_53]
6-26	1053-1057	pain	abstract[53]	giv[53]	_	_
6-27	1058-1061	and	_	_	_	_
6-28	1062-1069	reduced	_	_	_	_
6-29	1070-1077	numbers	quantity[54]	new[54]	_	_
6-30	1078-1080	of	quantity[54]	new[54]	_	_
6-31	1081-1092	accumulated	quantity[54]|object[55]	new[54]|giv[55]	coref	15-39[136_55]
6-32	1093-1097	mast	quantity[54]|object[55]	new[54]|giv[55]	_	_
6-33	1098-1103	cells	quantity[54]|object[55]	new[54]|giv[55]	_	_
6-34	1104-1106	in	quantity[54]|object[55]	new[54]|giv[55]	_	_
6-35	1107-1110	the	quantity[54]|object[55]|object[56]	new[54]|giv[55]|new[56]	coref	9-28[0_56]
6-36	1111-1119	affected	quantity[54]|object[55]|object[56]	new[54]|giv[55]|new[56]	_	_
6-37	1120-1126	tissue	quantity[54]|object[55]|object[56]	new[54]|giv[55]|new[56]	_	_
6-38	1127-1128	.	_	_	_	_

#Text=Here , we examined the potential of a common household chemical , 2-methyl-4-isothiazolin-3-one/methylisothiazolinone ( MI ) , to induce contact hypersensitivity reactions and consequent allergy-driven genital pain in ND4 female outbred mice .
7-1	1129-1133	Here	_	_	_	_
7-2	1134-1135	,	_	_	_	_
7-3	1136-1138	we	person	giv	ana	12-1
7-4	1139-1147	examined	_	_	_	_
7-5	1148-1151	the	abstract[58]	new[58]	_	_
7-6	1152-1161	potential	abstract[58]	new[58]	_	_
7-7	1162-1164	of	abstract[58]	new[58]	_	_
7-8	1165-1166	a	abstract[58]|substance[60]	new[58]|new[60]	coref	13-9[118_60]
7-9	1167-1173	common	abstract[58]|substance[60]	new[58]|new[60]	_	_
7-10	1174-1183	household	abstract[58]|place|substance[60]	new[58]|new|new[60]	coref	8-15
7-11	1184-1192	chemical	abstract[58]|substance[60]	new[58]|new[60]	_	_
7-12	1193-1194	,	abstract[58]	new[58]	_	_
7-13	1195-1246	2-methyl-4-isothiazolin-3-one/methylisothiazolinone	abstract[58]|object	new[58]|new	appos	7-15
7-14	1247-1248	(	_	_	_	_
7-15	1249-1251	MI	object	giv	coref	8-1
7-16	1252-1253	)	_	_	_	_
7-17	1254-1255	,	_	_	_	_
7-18	1256-1258	to	_	_	_	_
7-19	1259-1265	induce	_	_	_	_
7-20	1266-1273	contact	_	_	_	_
7-21	1274-1290	hypersensitivity	abstract|event[64]	giv|new[64]	_	_
7-22	1291-1300	reactions	event[64]	new[64]	_	_
7-23	1301-1304	and	_	_	_	_
7-24	1305-1315	consequent	abstract[65]	giv[65]	coref	10-24[97_65]
7-25	1316-1330	allergy-driven	abstract[65]	giv[65]	_	_
7-26	1331-1338	genital	abstract[65]	giv[65]	_	_
7-27	1339-1343	pain	abstract[65]	giv[65]	_	_
7-28	1344-1346	in	abstract[65]	giv[65]	_	_
7-29	1347-1350	ND4	abstract[65]|animal[67]	giv[65]|giv[67]	coref	15-30[0_67]
7-30	1351-1357	female	abstract[65]|person|animal[67]	giv[65]|new|giv[67]	_	_
7-31	1358-1365	outbred	abstract[65]|animal[67]	giv[65]|giv[67]	_	_
7-32	1366-1370	mice	abstract[65]|animal[67]	giv[65]|giv[67]	_	_
7-33	1371-1372	.	_	_	_	_

#Text=MI is a biocide preservative present in soaps , shampoos , vaginal washes , household cleaners , and paints .
8-1	1373-1375	MI	substance	giv	coref	9-12
8-2	1376-1378	is	_	_	_	_
8-3	1379-1380	a	_	_	_	_
8-4	1381-1388	biocide	event	new	_	_
8-5	1389-1401	preservative	substance	new	_	_
8-6	1402-1409	present	_	_	_	_
8-7	1410-1412	in	_	_	_	_
8-8	1413-1418	soaps	substance	new	_	_
8-9	1419-1420	,	_	_	_	_
8-10	1421-1429	shampoos	object	new	_	_
8-11	1430-1431	,	_	_	_	_
8-12	1432-1439	vaginal	object[73]	new[73]	_	_
8-13	1440-1446	washes	object[73]	new[73]	_	_
8-14	1447-1448	,	_	_	_	_
8-15	1449-1458	household	place|object[75]	giv|new[75]	coref|coref	11-9|11-9
8-16	1459-1467	cleaners	object[75]	new[75]	_	_
8-17	1468-1469	,	_	_	_	_
8-18	1470-1473	and	_	_	_	_
8-19	1474-1480	paints	object	new	_	_
8-20	1481-1482	.	_	_	_	_

#Text=Recent evidence suggests that a significant portion of people exposed to MI developed the capacity for an allergic response , showed exacerbated inflammatory responses , and experienced tissue injury in the skin or lungs after exposure .
9-1	1483-1489	Recent	abstract[77]	new[77]	_	_
9-2	1490-1498	evidence	abstract[77]	new[77]	_	_
9-3	1499-1507	suggests	_	_	_	_
9-4	1508-1512	that	_	_	_	_
9-5	1513-1514	a	quantity[78]	new[78]	_	_
9-6	1515-1526	significant	quantity[78]	new[78]	_	_
9-7	1527-1534	portion	quantity[78]	new[78]	_	_
9-8	1535-1537	of	quantity[78]	new[78]	_	_
9-9	1538-1544	people	quantity[78]|person	new[78]|new	_	_
9-10	1545-1552	exposed	_	_	_	_
9-11	1553-1555	to	_	_	_	_
9-12	1556-1558	MI	abstract	giv	coref	10-4
9-13	1559-1568	developed	abstract|event|abstract	new|new|new	coref|coref|coref|none|none|none|coref|coref|coref|none|none|none|coref|coref|coref|none|none|none	10-20[95_0]|11-19[106_0]|12-18[114_0]|9-13[0_95]|9-13[0_106]|9-13[0_114]|10-20[95_0]|11-19[106_0]|12-18[114_0]|9-13[0_95]|9-13[0_106]|9-13[0_114]|10-20[95_0]|11-19[106_0]|12-18[114_0]|9-13[0_95]|9-13[0_106]|9-13[0_114]
9-14	1569-1572	the	abstract[81]	new[81]	_	_
9-15	1573-1581	capacity	abstract[81]	new[81]	_	_
9-16	1582-1585	for	abstract[81]	new[81]	_	_
9-17	1586-1588	an	abstract[81]|event[82]	new[81]|new[82]	_	_
9-18	1589-1597	allergic	abstract[81]|event[82]	new[81]|new[82]	_	_
9-19	1598-1606	response	abstract[81]|event[82]	new[81]|new[82]	_	_
9-20	1607-1608	,	_	_	_	_
9-21	1609-1615	showed	_	_	_	_
9-22	1616-1627	exacerbated	_	_	_	_
9-23	1628-1640	inflammatory	abstract[83]	giv[83]	coref	10-1[90_83]
9-24	1641-1650	responses	abstract[83]	giv[83]	_	_
9-25	1651-1652	,	_	_	_	_
9-26	1653-1656	and	_	_	_	_
9-27	1657-1668	experienced	_	_	_	_
9-28	1669-1675	tissue	object|event[85]	giv|new[85]	_	_
9-29	1676-1682	injury	event[85]	new[85]	_	_
9-30	1683-1685	in	event[85]	new[85]	_	_
9-31	1686-1689	the	event[85]|object[86]|abstract[87]	new[85]|giv[86]|giv[87]	_	_
9-32	1690-1694	skin	event[85]|object[86]|abstract[87]	new[85]|giv[86]|giv[87]	_	_
9-33	1695-1697	or	event[85]|abstract[87]	new[85]|giv[87]	_	_
9-34	1698-1703	lungs	event[85]|abstract[87]|object[88]	new[85]|giv[87]|new[88]	_	_
9-35	1704-1709	after	event[85]|abstract[87]|object[88]	new[85]|giv[87]|new[88]	_	_
9-36	1710-1718	exposure	event[85]|abstract[87]|object[88]|abstract	new[85]|giv[87]|new[88]|new	coref	14-15[123_0]
9-37	1719-1720	.	_	_	_	_

#Text=Allergic responses to MI have also been linked to vulvar dermatitis , but no connections between such dermatoses and the later development of vulvar pain have been made in the published clinical literature .
10-1	1721-1729	Allergic	abstract[90]	giv[90]	_	_
10-2	1730-1739	responses	abstract[90]	giv[90]	_	_
10-3	1740-1742	to	abstract[90]	giv[90]	_	_
10-4	1743-1745	MI	abstract[90]|abstract	giv[90]|giv	coref	14-4
10-5	1746-1750	have	_	_	_	_
10-6	1751-1755	also	_	_	_	_
10-7	1756-1760	been	_	_	_	_
10-8	1761-1767	linked	_	_	_	_
10-9	1768-1770	to	_	_	_	_
10-10	1771-1777	vulvar	abstract[92]	new[92]	_	_
10-11	1778-1788	dermatitis	abstract[92]	new[92]	_	_
10-12	1789-1790	,	_	_	_	_
10-13	1791-1794	but	_	_	_	_
10-14	1795-1797	no	abstract[93]	new[93]	_	_
10-15	1798-1809	connections	abstract[93]	new[93]	_	_
10-16	1810-1817	between	abstract[93]	new[93]	_	_
10-17	1818-1822	such	abstract[93]|abstract[94]	new[93]|new[94]	_	_
10-18	1823-1833	dermatoses	abstract[93]|abstract[94]	new[93]|new[94]	_	_
10-19	1834-1837	and	_	_	_	_
10-20	1838-1841	the	abstract[95]	new[95]	_	_
10-21	1842-1847	later	abstract[95]	new[95]	_	_
10-22	1848-1859	development	abstract[95]	new[95]	_	_
10-23	1860-1862	of	abstract[95]	new[95]	_	_
10-24	1863-1869	vulvar	abstract[95]|object|abstract[97]	new[95]|giv|giv[97]	coref|coref	12-21[115_97]|12-21[115_97]
10-25	1870-1874	pain	abstract[95]|abstract[97]	new[95]|giv[97]	_	_
10-26	1875-1879	have	_	_	_	_
10-27	1880-1884	been	_	_	_	_
10-28	1885-1889	made	_	_	_	_
10-29	1890-1892	in	_	_	_	_
10-30	1893-1896	the	abstract[98]	new[98]	_	_
10-31	1897-1906	published	abstract[98]	new[98]	_	_
10-32	1907-1915	clinical	abstract[98]	new[98]	_	_
10-33	1916-1926	literature	abstract[98]	new[98]	_	_
10-34	1927-1928	.	_	_	_	_

#Text=Recently , Reed and colleagues identified exposures to household and workplace chemicals as a possible risk factor for the development of vulvodynia .
11-1	1929-1937	Recently	_	_	_	_
11-2	1938-1939	,	_	_	_	_
11-3	1940-1944	Reed	person	new	_	_
11-4	1945-1948	and	_	_	_	_
11-5	1949-1959	colleagues	person	new	_	_
11-6	1960-1970	identified	_	_	_	_
11-7	1971-1980	exposures	abstract[101]	new[101]	coref	12-15[113_101]
11-8	1981-1983	to	abstract[101]	new[101]	_	_
11-9	1984-1993	household	abstract[101]|place	new[101]|giv	_	_
11-10	1994-1997	and	abstract[101]	new[101]	_	_
11-11	1998-2007	workplace	abstract[101]|place|substance[104]	new[101]|new|new[104]	_	_
11-12	2008-2017	chemicals	abstract[101]|substance[104]	new[101]|new[104]	_	_
11-13	2018-2020	as	_	_	_	_
11-14	2021-2022	a	_	_	_	_
11-15	2023-2031	possible	_	_	_	_
11-16	2032-2036	risk	abstract	new	_	_
11-17	2037-2043	factor	_	_	_	_
11-18	2044-2047	for	_	_	_	_
11-19	2048-2051	the	event[106]	new[106]	_	_
11-20	2052-2063	development	event[106]	new[106]	_	_
11-21	2064-2066	of	event[106]	new[106]	_	_
11-22	2067-2077	vulvodynia	event[106]|abstract	new[106]|giv	coref	13-7
11-23	2078-2079	.	_	_	_	_

#Text=Our previously published mouse models demonstrated the biological plausibility of the epidemiological link between chemical exposures and the development of genital pain .
12-1	2080-2083	Our	person|abstract[110]	giv|giv[110]	ana|ana	14-1|14-1
12-2	2084-2094	previously	abstract[110]	giv[110]	_	_
12-3	2095-2104	published	abstract[110]	giv[110]	_	_
12-4	2105-2110	mouse	animal|abstract[110]	giv|giv[110]	_	_
12-5	2111-2117	models	abstract[110]	giv[110]	_	_
12-6	2118-2130	demonstrated	_	_	_	_
12-7	2131-2134	the	abstract[111]	new[111]	_	_
12-8	2135-2145	biological	abstract[111]	new[111]	_	_
12-9	2146-2158	plausibility	abstract[111]	new[111]	_	_
12-10	2159-2161	of	abstract[111]	new[111]	_	_
12-11	2162-2165	the	abstract[111]|abstract[112]	new[111]|new[112]	coref	13-3[116_112]
12-12	2166-2181	epidemiological	abstract[111]|abstract[112]	new[111]|new[112]	_	_
12-13	2182-2186	link	abstract[111]|abstract[112]	new[111]|new[112]	_	_
12-14	2187-2194	between	abstract[111]|abstract[112]	new[111]|new[112]	_	_
12-15	2195-2203	chemical	abstract[111]|abstract[112]|abstract[113]	new[111]|new[112]|giv[113]	_	_
12-16	2204-2213	exposures	abstract[111]|abstract[112]|abstract[113]	new[111]|new[112]|giv[113]	_	_
12-17	2214-2217	and	abstract[111]|abstract[112]|abstract[113]	new[111]|new[112]|giv[113]	_	_
12-18	2218-2221	the	abstract[111]|abstract[112]|abstract[113]|abstract[114]	new[111]|new[112]|giv[113]|new[114]	_	_
12-19	2222-2233	development	abstract[111]|abstract[112]|abstract[113]|abstract[114]	new[111]|new[112]|giv[113]|new[114]	_	_
12-20	2234-2236	of	abstract[111]|abstract[112]|abstract[113]|abstract[114]	new[111]|new[112]|giv[113]|new[114]	_	_
12-21	2237-2244	genital	abstract[111]|abstract[112]|abstract[113]|abstract[114]|abstract[115]	new[111]|new[112]|giv[113]|new[114]|giv[115]	coref	14-21[125_115]
12-22	2245-2249	pain	abstract[111]|abstract[112]|abstract[113]|abstract[114]|abstract[115]	new[111]|new[112]|giv[113]|new[114]|giv[115]	_	_
12-23	2250-2251	.	_	_	_	_

#Text=However , a specific link between vulvodynia and a known environmental chemical does not yet exist .
13-1	2252-2259	However	_	_	_	_
13-2	2260-2261	,	_	_	_	_
13-3	2262-2263	a	abstract[116]	giv[116]	_	_
13-4	2264-2272	specific	abstract[116]	giv[116]	_	_
13-5	2273-2277	link	abstract[116]	giv[116]	_	_
13-6	2278-2285	between	abstract[116]	giv[116]	_	_
13-7	2286-2296	vulvodynia	abstract[116]|substance	giv[116]|giv	_	_
13-8	2297-2300	and	abstract[116]	giv[116]	_	_
13-9	2301-2302	a	abstract[116]|substance[118]	giv[116]|giv[118]	_	_
13-10	2303-2308	known	abstract[116]|substance[118]	giv[116]|giv[118]	_	_
13-11	2309-2322	environmental	abstract[116]|substance[118]	giv[116]|giv[118]	_	_
13-12	2323-2331	chemical	abstract[116]|substance[118]	giv[116]|giv[118]	_	_
13-13	2332-2336	does	_	_	_	_
13-14	2337-2340	not	_	_	_	_
13-15	2341-2344	yet	_	_	_	_
13-16	2345-2350	exist	_	_	_	_
13-17	2351-2352	.	_	_	_	_

#Text=We suggest that MI is a plausible candidate for an environmental irritant/allergen , and that exposure to MI might drive allergy-provoked pain .
14-1	2353-2355	We	person	giv	ana	15-3
14-2	2356-2363	suggest	_	_	_	_
14-3	2364-2368	that	_	_	_	_
14-4	2369-2371	MI	person	giv	coref	14-6[121_0]
14-5	2372-2374	is	_	_	_	_
14-6	2375-2376	a	person[121]	giv[121]	coref	14-18[0_121]
14-7	2377-2386	plausible	person[121]	giv[121]	_	_
14-8	2387-2396	candidate	person[121]	giv[121]	_	_
14-9	2397-2400	for	person[121]	giv[121]	_	_
14-10	2401-2403	an	person[121]|abstract[122]	giv[121]|new[122]	_	_
14-11	2404-2417	environmental	person[121]|abstract[122]	giv[121]|new[122]	_	_
14-12	2418-2435	irritant/allergen	person[121]|abstract[122]	giv[121]|new[122]	_	_
14-13	2436-2437	,	_	_	_	_
14-14	2438-2441	and	_	_	_	_
14-15	2442-2446	that	abstract[123]	giv[123]	_	_
14-16	2447-2455	exposure	abstract[123]	giv[123]	_	_
14-17	2456-2458	to	abstract[123]	giv[123]	_	_
14-18	2459-2461	MI	abstract[123]|abstract	giv[123]|giv	coref	15-6
14-19	2462-2467	might	_	_	_	_
14-20	2468-2473	drive	_	_	_	_
14-21	2474-2490	allergy-provoked	abstract[125]	giv[125]	_	_
14-22	2491-2495	pain	abstract[125]	giv[125]	_	_
14-23	2496-2497	.	_	_	_	_

#Text=Here , we repeatedly applied MI dissolved in saline ( a surrogate for water-based cleansers that typically contain MI as a preservative ) topically within the vaginal canals of mice and characterized consequent allergic inflammation , accumulation of mast cells , and ano-genital sensitivity to pressure .
15-1	2498-2502	Here	_	_	_	_
15-2	2503-2504	,	_	_	_	_
15-3	2505-2507	we	person	giv	ana	16-1
15-4	2508-2518	repeatedly	_	_	_	_
15-5	2519-2526	applied	_	_	_	_
15-6	2527-2529	MI	substance	giv	coref	15-19
15-7	2530-2539	dissolved	_	_	_	_
15-8	2540-2542	in	_	_	_	_
15-9	2543-2549	saline	substance	new	_	_
15-10	2550-2551	(	_	_	_	_
15-11	2552-2553	a	object[129]	new[129]	_	_
15-12	2554-2563	surrogate	object[129]	new[129]	_	_
15-13	2564-2567	for	object[129]	new[129]	_	_
15-14	2568-2579	water-based	object[129]|substance[130]	new[129]|new[130]	_	_
15-15	2580-2589	cleansers	object[129]|substance[130]	new[129]|new[130]	_	_
15-16	2590-2594	that	_	_	_	_
15-17	2595-2604	typically	_	_	_	_
15-18	2605-2612	contain	_	_	_	_
15-19	2613-2615	MI	substance	giv	_	_
15-20	2616-2618	as	_	_	_	_
15-21	2619-2620	a	_	_	_	_
15-22	2621-2633	preservative	_	_	_	_
15-23	2634-2635	)	_	_	_	_
15-24	2636-2645	topically	_	_	_	_
15-25	2646-2652	within	_	_	_	_
15-26	2653-2656	the	place[132]	new[132]	_	_
15-27	2657-2664	vaginal	place[132]	new[132]	_	_
15-28	2665-2671	canals	place[132]	new[132]	_	_
15-29	2672-2674	of	place[132]	new[132]	_	_
15-30	2675-2679	mice	place[132]|animal	new[132]|giv	_	_
15-31	2680-2683	and	_	_	_	_
15-32	2684-2697	characterized	_	_	_	_
15-33	2698-2708	consequent	abstract[134]	giv[134]	_	_
15-34	2709-2717	allergic	abstract[134]	giv[134]	_	_
15-35	2718-2730	inflammation	abstract[134]	giv[134]	_	_
15-36	2731-2732	,	_	_	_	_
15-37	2733-2745	accumulation	object[135]	new[135]	_	_
15-38	2746-2748	of	object[135]	new[135]	_	_
15-39	2749-2753	mast	object[135]|object[136]	new[135]|giv[136]	_	_
15-40	2754-2759	cells	object[135]|object[136]	new[135]|giv[136]	_	_
15-41	2760-2761	,	_	_	_	_
15-42	2762-2765	and	_	_	_	_
15-43	2766-2777	ano-genital	abstract[137]	giv[137]	coref	16-24[147_137]
15-44	2778-2789	sensitivity	abstract[137]	giv[137]	_	_
15-45	2790-2792	to	abstract[137]	giv[137]	_	_
15-46	2793-2801	pressure	abstract[137]|abstract	giv[137]|new	_	_
15-47	2802-2803	.	_	_	_	_

#Text=We also assessed the effects of therapeutic and preventive administration of topical THC treatments in the vaginal canal on mast cell abundance and painful sensitivity .
16-1	2804-2806	We	person	giv	_	_
16-2	2807-2811	also	_	_	_	_
16-3	2812-2820	assessed	_	_	_	_
16-4	2821-2824	the	abstract[140]	new[140]	_	_
16-5	2825-2832	effects	abstract[140]	new[140]	_	_
16-6	2833-2835	of	abstract[140]	new[140]	_	_
16-7	2836-2847	therapeutic	abstract[140]|organization[141]	new[140]|new[141]	_	_
16-8	2848-2851	and	abstract[140]|organization[141]	new[140]|new[141]	_	_
16-9	2852-2862	preventive	abstract[140]|organization[141]	new[140]|new[141]	_	_
16-10	2863-2877	administration	abstract[140]|organization[141]	new[140]|new[141]	_	_
16-11	2878-2880	of	abstract[140]|organization[141]	new[140]|new[141]	_	_
16-12	2881-2888	topical	abstract[140]|organization[141]|abstract[143]	new[140]|new[141]|new[143]	_	_
16-13	2889-2892	THC	abstract[140]|organization[141]|abstract|abstract[143]	new[140]|new[141]|giv|new[143]	_	_
16-14	2893-2903	treatments	abstract[140]|organization[141]|abstract[143]	new[140]|new[141]|new[143]	_	_
16-15	2904-2906	in	abstract[140]|organization[141]|abstract[143]	new[140]|new[141]|new[143]	_	_
16-16	2907-2910	the	abstract[140]|organization[141]|abstract[143]|place[144]	new[140]|new[141]|new[143]|giv[144]	_	_
16-17	2911-2918	vaginal	abstract[140]|organization[141]|abstract[143]|place[144]	new[140]|new[141]|new[143]|giv[144]	_	_
16-18	2919-2924	canal	abstract[140]|organization[141]|abstract[143]|place[144]	new[140]|new[141]|new[143]|giv[144]	_	_
16-19	2925-2927	on	abstract[140]|organization[141]|abstract[143]|place[144]	new[140]|new[141]|new[143]|giv[144]	_	_
16-20	2928-2932	mast	abstract[140]|organization[141]|abstract[143]|place[144]|abstract[146]	new[140]|new[141]|new[143]|giv[144]|new[146]	_	_
16-21	2933-2937	cell	abstract[140]|organization[141]|abstract[143]|place[144]|place|abstract[146]	new[140]|new[141]|new[143]|giv[144]|new|new[146]	_	_
16-22	2938-2947	abundance	abstract[140]|organization[141]|abstract[143]|place[144]|abstract[146]	new[140]|new[141]|new[143]|giv[144]|new[146]	_	_
16-23	2948-2951	and	abstract[140]|organization[141]|abstract[143]|place[144]	new[140]|new[141]|new[143]|giv[144]	_	_
16-24	2952-2959	painful	abstract[140]|organization[141]|abstract[143]|place[144]|abstract[147]	new[140]|new[141]|new[143]|giv[144]|giv[147]	_	_
16-25	2960-2971	sensitivity	abstract[140]|organization[141]|abstract[143]|place[144]|abstract[147]	new[140]|new[141]|new[143]|giv[144]|giv[147]	_	_
16-26	2972-2973	.	_	_	_	_
